Cat. No. | Product name | CAS No. |
DCC3362 |
Minigastrin I (human)
Inhibitor of cholecystokinin B receptors (CCK2) |
54405-27-5 |
DCC3363 |
Mip-1072
Novel inhibitor of the prostate-specific membrane antigen (PSMA) |
949575-20-6 |
DCC3364 |
Mip-1095
Novel inhibitor of the prostate-specific membrane antigen (PSMA) |
949575-22-8 |
DCC3365 |
Mipe-1686
Novel long-lasting myostatin inhibitor, significantly increasing muscle mass and hindlimb grip strength in Duchenne muscular dystrophic model mice |
|
DCC3366 |
Mips1455
Novel photoactivatable allosteric ligand for the M1 muscarinic acetylcholine receptor |
1627580-82-8 |
DCC3367 |
Mips1780
Novel selective positive allosteric modulator (PAM) at the M1 muscarinic acetylcholine receptor |
|
DCC3368 |
Mipsagargin
Novel thapsigargin-based PSMA-activated prodrug, inhibiting the sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump protein |
1245732-48-2 |
DCC3369 |
Mir-21 Inhibitor
Novel specific and efficient inhibitor of miR-21 expression, inducing a 485% increase in the luciferase reporter signal at 10 μM |
|
DCC3370 |
Mir-21 Inhibitor-1
Novel inhibitor of microRNA-21 (miR-21) |
304880-74-8 |
DCC3371 |
Miro1 Reducer
Novel Miro1 degrader, rescuing dopaminergic neurodegeneration and promoting Miro1 degradation in Parkinson’s Disease fibroblasts |
|
DCC3372 |
Miro1 Reducer 3
Novel degrader of Miro1 (mitochondrial Rho GTPase 1), reducing Miro1 levels in fibroblasts and stress-induced degeneration of dopaminergic neurons derived from Parkinson's disease (PD) patients, as well as age-dependent neuronal loss and prolongs lifespan |
|
DCC3373 |
miroistonil
Novel inhibitor of AMA1-RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Antidepressant; Acetylcholinesterase inhibitor |
33299-81-9 |
DCC3374 |
mitf-in-17
The first small molecule inhibitor of Mitf-E-box DNA binding with depigmenting activity |
313984-78-0 |
DCC3375 |
Mitobady
Sensitive and specific Raman probe for live cell imaging of mitochondria |
1644119-76-5 |
DCC3376 |
Mitodpp-2
Fluorescent probe for measuring the activity levels of erasers of S-palmitoylation, acyl-protein thioesterases (APTs), within mitochondria of live cells |
|
DCC3377 |
Mitoebselen-2
Radiation Mitigator, reducing lipid hydroperoxides and preventing apoptotic cell death |
|
DCC3378 |
Mitofp
Novel mitochondrial-targeted pan-APT inhibitor |
|
DCC3379 |
Mito-peg5-ato
Novel potent antiproliferative mitochondria-targeted OXPHOS inhibitor (IC50=38 nM) in MiaPaCa-2 cells, being more effective than other inhibitors of OXPHOS in MiaPaCa-2 and U87MG cells |
|
DCC3380 |
mitopy1
Novel selective fluorescent H2O2 probe, tracking the mitochondria of live biological specimens and responds to local fluxes of hydrogen peroxide (H2O2) by a turn-on fluorescence enhancement |
1041634-69-8 |
DCC3381 |
Mitozolomide
Antineoplastic DNA alkylating agent |
85622-95-3 |
DCC3382 |
Mizoribine Mono-phosphate
Specific inhibitor of the cellular inosine-5-monophosphate dehydrogenase (IMPDH); Immunosuppressive agent |
62025-48-3 |
DCC3383 |
Mk0359
Potent and selective PDE4 inhibitor |
346629-30-9 |
DCC3384 |
Mk-0493
Novel potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R) |
455956-93-1 |
DCC3385 |
mk-0499
The class III antiarrhythmic agent, blocking HERG, a human cardiac delayed rectifier K+ channel |
156619-48-6 |
DCC3386 |
Mk-0626
Novel Dipeptidyl peptidase IV (DPP-4) inhibitor, improving neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression |
|
DCC3387 |
Mk-0633 Tosylate
Potent and Selective 5-Lipoxygenase Inhibitor |
1137737-87-1 |
DCC3388 |
Mk-0736
Selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor |
719272-79-4 |
DCC3389 |
Mk-0916
Selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor |
633317-53-0 |
DCC3390 |
Mk-1220
Novel Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure |
924270-31-5 |
DCC3391 |
Mk-1597
Novel renin inhibitor |
1007392-69-9 |
DCC3392 |
Mk-2295
Potent TRPV1 antagonist |
878811-00-8 |
DCC3393 |
Mk-386
Potent and selective human type-1 5alpha-reductase inhibitor |
158493-17-5 |
DCC3394 |
Mk-4541
Novel Selective Androgen Receptor Modulator (SARM) |
796885-38-6 |
DCC3395 |
Mk-5046
Novel nonpeptide bombesin receptor subtype-3 agonist |
1022152-70-0 |
DCC3396 |
Mk-6884
Novel potent muscarinic acetylcholine receptor 4 (M4) positive allosteric modulator (PAM) |
|
DCC3397 |
Mk-7725
Novel bombesin receptor subtype-3 (BRS-3) modulator |
1034152-95-8 |
DCC3398 |
Mk-8245 Analog
Novel liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) |
1030612-87-3 |
DCC3399 |
Mk-8666 Tromethamine
Novel agonist of G-protein coupled receptor 40 (GPR40) |
2056254-98-7 |
DCC3400 |
Mk-8970
Prodrug of raltegravir with enhanced colonic absorption |
|
DCC3401 |
Mkk3/6-in-6
Novel potent and selective MKK3/6 inhibitor |
|
DCC3402 |
Mkp5-in-1
Novel highly specific, potent, orally bioavailable MKP5 inhibitor |
|
DCC3403 |
Km04794
Novel endoplasmic reticulum proteostasis modulator, enhancing insulin production in pancreatic β cells, inhibiting the UPR, alleviating ER stress and protein aggregation, improving intracellular insulin levels and insulin secretion |
882287-24-3 |
DCC3404 |
ml312
Novel Inhibitor of Scavenger Receptor BI-mediated Lipid Uptake |
1223559-59-8 |
DCC3405 |
Mlck Inhibitor Peptide-18
Selective inhibitor of Myosin Light Chain Kinase (MLCK) |
224579-74-2 |
DCC3406 |
Mln-0415
Novel IKK2 inhibitor, decreasing NF-κB activation and down-regulating the expression of a number of inflammatory proteins |
1147862-78-9 |
DCC3407 |
Mln944
Novel potent DNA binding agent, stabilizing topoisomerase-dependent cleavage, demonstrating exceptional efficacy against a number of murine and human tumor models |
343247-32-5 |
DCC3408 |
Mln-977
Second generation 5-LO inhibitor, blocking the production of leukotrienes |
175212-04-1 |
DCC3409 |
Mls000099089
Novel selective and potent inhibitor of recombinant h12/15-LOX and cellular mouse 12/15-LOX (m12/15-LOX) |
1164497-58-8 |
DCC3410 |
Mls000536924
Potent and selective competitive inhibitor of human epithelial 15-lipoxygenase-2 (15-LOX-2) |
511306-37-9 |
DCC3411 |
Mls000545091
Potent and selective mixed-type inhibitor of human epithelial 15-lipoxygenase-2 (15-LOX-2) |
322666-76-2 |
DCC3412 |
Mls000733230
Novel potent inhibitor of EBOV infection |
|
DCC3413 |
Mls001158554
Novel Inhibitor of Human Cytomegalovirus |
|
DCC3414 |
Mls-2064
Potent inhibitor of STAT3 and Akt signaling |
906660-74-0 |
DCC3415 |
Mls-2384
Novel dual JAK/Src kinase inhibitor, suppressing growth of diverse cancer cells |
1067884-45-0 |
DCC3416 |
Mls8091
Novel inhibitor of human cytomegalovirus (HCMV) infection |
848217-46-9 |
DCC3417 |
Ml-sa3
Potent agonist of TRPML channels specifically activating lysosomal ML1 currents |
570381-68-9 |
DCC3418 |
Mlt-695
Novel potent and selective MALT-1 protease inhibitor, showing improved solubility and permeability in comparison with MLT-748 |
|
DCC3419 |
Mmg-0358
Novel potent IDO1 inhibitor, showing low cytotoxicity and higher selectivity for IDO1 over TDO enzyme |
1378976-02-3 |
DCC3420 |
Mmh371
Novel potent and selective HDAC8 inhibitor |
|
DCC3421 |
Mmh409
Novel potent and selective HDAC8 inhibitor |
|
DCC3422 |
Mmh410
Novel potent and selective HDAC8 inhibitor |
|
DCC3423 |
Mmp13-in-t26c
Novel highly potent and selective MMP13 inhibitor |
869298-22-6 |
DCC3424 |
M-mpep
Negative allosteric modulator (NAM) ligand for the mGlu5 receptor |
|
DCC3425 |
Mmpl3-in-e11
Novel Mmpl3 inhibitor, indirectly blocking translocation of Trehalose Monomycolates across the IM |
923204-35-7 |
DCC3426 |
Mms-350
Highly water-soluble antifibrotic agent, reducing the profibrotic phenotype induced in vitro in primary human fibroblasts and ameliorating bleomycin-induced pulmonary fibrosis in vivo |
|
DCC3427 |
Mmv001239
Novel inhibitor of lanosterol-14-alpha-demethylase (TcCyp51) |
|
DCC3428 |
Mmv006764
The first small-molecule anti-plasmodial agent, disrupting rosetting, simultaneously restoring microcirculation and reduce parasite load |
|
DCC3429 |
Mmv007564
Novel antimalarial agent against asexual stages of P. falciparum |
950291-33-5 |
DCC3430 |
Mmv007839
Novel potent Plasmodium lactate transporter PfFNT |
381710-03-8 |
DCC3431 |
Mmv008138
Novel MEP pathway-targeting antimalarial agent |
1217513-24-0 |
DCC3432 |
Mmv009108
Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones |
|
DCC3433 |
Mmv019662
Novel Inhibitor of Plasmodium falciparum |
|
DCC3434 |
Mmv022029
Novel antischistosomal agent against chronic S. mansoni infection |
|
DCC3435 |
Mmv022478
Novel antischistosomal agent against chronic S. mansoni infection |
|
DCC3436 |
Mmv028038
Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones |
|
DCC3437 |
Mmv085203
Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites |
385419-89-6 |
DCC3438 |
Mmv396719
Novel antimalarial agent against Plasmodium falciparum |
848218-16-6 |
DCC3439 |
Mmv665916
Novel antimalarial agent, targeting P. falciparum farnesyltransferase PfFT, showing remarkable growth inhibition with EC50 value of 0.4 µM and presenting good selectivity index (SI > 250) |
896356-25-5 |
DCC3440 |
Mmv666693
Selective allosteric inhibitor of Plasmodium Kinesin-5 |
312527-99-4 |
DCC3441 |
Mmv675939
Novel potent inhibitor of P. falciparum asexual blood stages, inhibiting heme detoxification |
|
DCC3442 |
Mmv676477
Novel potent broad antiparasitic agent against intracellular Leishmania amastigotes, Trypanosoma brucei, and Plasmodium falciparum |
1003799-04-9 |
DCC3443 |
Mmv693183
First-in-class acetyl-CoA synthetase (AcAS) inhibitor, showong single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocking P. falciparum transmission to Anopheles mosquitoes |
|
DCC3444 |
Mnd Oxalate
Novel anticancer agent, inducing apoptosis, inhibiting migration and invasion |
|
DCC3445 |
Mnk1/2-in-9
Novel highly potent and selective MNK1/2 kinases inhibitor |
|
DCC3446 |
Mnk2-in-8e
Potent and selective Mnk2 inhibitor |
|
DCC3447 |
Mntmpyp Pentachloride
Cell-permeable superoxide dismutase (SOD) mimetic |
100012-18-8 |
DCC3448 |
Molibresib Besylate
Novel inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity |
1895049-20-3 |
DCC3449 |
Momelotinib Dihydrochloride
Featured
Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis. |
1380317-28-1 |
DCC3450 |
Momordicoside L
Natural antioxidant and antidiabetic agent |
81348-83-6 |
DCC3451 |
Mon-dnj
Novel iminosugar, downregulatiing the interferon γ receptor by dengue virus |
615253-61-7 |
DCC3452 |
Moracin T
Natural potent antioxidant agent |
1146113-27-0 |
DCC3453 |
Morellic Acid
Natural analogue of (-)-gambogic acid acting as a potent inhibitor of global predominant MRSA USA300 |
5304-71-2 |
DCC3454 |
Mosapramine Dihydrochloride
Potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors, and with moderate affinity for the 5-HT2 receptors |
98043-60-8 |
DCC3455 |
Naucledine
Natural antibacterial, antileishmanial, and antifungal agent |
26238-84-6 |
DCC3456 |
Mp-10 Succinate
Potent and Specific PDE10A inhibitor |
1037309-45-7 |
DCC3457 |
Mp1104
Novel mixed kappa-delta opioid receptor agonist with anti-cocaine properties and reduced side-effects in rats |
|
DCC3458 |
Mpges-1 Inhibitor-2
Novel potent and selective microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor |
|
DCC3459 |
mpi621
Novel anti-cancer agent, being more potent and safer than conventional indomethacin |
1428774-23-5 |
DCC3460 |
Mpk576
Novel selective class IIb histone deacetylase inhibitor (HDACi), dose-dependently decreasing the viability of Acanthamoeba trophozoites |
|
DCC3461 |
Mpo-0029
Potent and selective COX-2 inhibitor |
248281-84-8 |
DCC3462 |
Mpp Dihydrochloride
Specific estrogen receptor α (ERα) antagonist |
911295-24-4 |
DCC3463 |
Mpro-in-n3
Novel main protease (Mpro) inhibitor, inhibiting MHV-A29, HCoV-229E, FOPV replication, and SARS-CoV-2 viral cell entry |
884650-98-0 |
DCC3464 |
mps1 Inhibitor I
Novel Mps1 Kinase Inhibitor |
1226900-59-9 |
DCC3465 |
Mps-bay2b
Novel inhibitor of MPS1 |
1263420-68-3 |
DCC3466 |
Mpt0b206
Novel tubulin polymerization inhibitor |
|
DCC3467 |
Mpt0b451
Novel Dual HDAC6 and Tubulin Inhibitor, Displaying Anti-tumor Ability in Human Cancer Cells |
|
DCC3468 |
Mptp-in-22
Novel mitochondrial permeability transition pore (mPTP) inhibitor |
1223569-03-6 |
DCC3469 |
Mpx-007
Novel potent and selective antagonist of GluN2A-containing NMDA receptors |
1688685-29-1 |
DCC3470 |
Mq02-439
Novel highly potent and selective 5-HT2C agonist |
|
DCC3471 |
Mr22388
Novel, potent inducer of apoptosis via the MAP kinase pathways. Inhibitor of several kinases including the tyrosine kinase FLT3-ITD |
258270-07-4 |
DCC3472 |
Mr6-31-2
Novel inhibitor of the main protease (Mpro) of SARS-CoV-2 |
|
DCC3473 |
Mrgprx1 Pam 1t
Novel positive allosteric modulator (PAM) of mas-related G protein-coupled receptor X1 (MRGPRX1), reducing behavioral heat hypersensitivity in humanized MRGPRX1 mice, demonstrating the therapeutic potential in treating neuropathic pain |
|
DCC3474 |
Mrgx1-activator-1
Activator of MrgX1 receptor signaling |
793731-95-0 |
DCC3475 |
Mri-1891
Novel peripheral CB1R antagonist, being highly biased toward inhibiting CB1R-induced β-arrestin-2 (βArr2) recruitment over G-protein activation |
|
DCC3476 |
Mrl-248
Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
DCC3477 |
Mrl-299
Novel potent RORγT inhibitor |
|
DCC3478 |
Mrl-367
Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
DCC3479 |
Mrl-770
Novel selective and reproducible inhibitor of DNA synthesis in E. coli JL553 |
|
DCC3480 |
Mrs2220
Selective enhancer of the ATP effects at fast desensitizing P2X (P2X1 and P2X3) receptors |
1027168-08-6 |
DCC3481 |
mrs2690
Potent P2Y14 receptor agonist |
15039-58-4 |
DCC3482 |
mrs2693 Trisodium
Selective P2Y6 agonist |
911391-37-2 |
DCC3483 |
mrs2768
Selective P2Y2 agonist |
1047980-83-5 |
DCC3484 |
mrs2957
Potent P2Y6 agonist |
1228271-30-4 |
DCC3485 |
Mrs2964
Potent and selective P2Y6 receptor agonist |
|
DCC3486 |
Mrs4598
Novel highly potent human CD73 inhibitor (K i = 0.673 nM) |
|
DCC3487 |
Mrs4608
Novel potent antagonist of P2Y 14 receptor (P2Y 14 R) (IC 50 ~20 nM at hP2Y 14 R/mP2Y 14 R) |
|
DCC3488 |
Mrs4654
Novel potent P2Y14 Receptor Antagonist (IC 50 , 15 nM) |
|
DCC3489 |
Mrs7396
Bitopic fluorescent antagonist of the A2A adenosine receptor |
|
DCC3490 |
Mrs7469
Novel highly selective A1 adenosine receptor (A1AR) agonist |
|
DCC3491 |
Mrs7591
Novel Partial Agonist of Human and Mouse A3 Adenosine Receptors (Ki = 10.9/17.8 nM, at human/mouse A3AR) |
|
DCC3492 |
Mrs7799
Novel highly potent A3 adenosine receptor (A3AR) antagonist with Kd values (nM): 0.55 (human), 3.74 (mouse), and 2.80 (rat) |
|
DCC3493 |
Mrt-68601 Hydrochloride
Potent inhibitor of TANK-binding kinase-1 (TBK1)/IKKepislon kinases |
1962928-25-1 |
DCC3494 |
Mrt-92 Hydrochloride
Novel inhibitor of Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor |
1428307-52-1 |
DCC3495 |
Mrz-8676
Novel, selective, orally bioavailable, negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5) |
872122-36-6 |
DCC3496 |
ms0017509
Inhibitor of DNA damage repair |
21945-37-9 |
DCC3497 |
ms0019266
Novel inhibitor of DNA damage repair |
124285-22-9 |
DCC3498 |
Ms2126
Novel inhibitor of Human p53 and CREB Binding Protein (CREBBP) interaction |
16078-42-5 |
DCC3499 |
Ms2177
Novel potent and selective SETD8 inhibitor |
|
DCC3500 |
Ms2i6a
Mitochondrial tRNA-specific modification, regulating efficient mitochondrial translation and energy metabolism in mammals |
20859-00-1 |
DCC3501 |
Msc2524070
Novel potent tankyrase (TNKS) inhibitor (EC 50 : 2 nM) |
|
DCC3502 |
Msc-4381
Novel inhibitor of SLC16A3 |
|
DCC3503 |
Msd-496486311
Novel potent and selective PI3Kδ inhibitor |
|
DCC3504 |
Msk-195
Potent TRPV1 agonist |
289902-82-5 |
DCC3505 |
Mßl-in-2i
Novel potent broad-spectrum metallo-β-lactamase (MβL) inhibitor, inhibiting the MβLs NDM-1, VIM-2, ImiS, and L1 |
305376-89-0 |
DCC3506 |
Mt1/2 Agonist (s)-3b
Novel BBB permeable potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes |
|
DCC3507 |
Mtc420
Novel antituberculosis agent. targeting the respiratory chain of Mycobacterium tuberculosis (Mtb) and being effective against multi drug resistant (MDR) Mtb |
2088930-66-7 |
DCC3508 |
Mtd12813
Novel minimized theta-defensin, being highly effective against CRE pathogens K. pneumoniae and E. coli in vivo, significantly enhancing survival by promoting rapid host-mediated bacterial clearance and by modulating pathologic cytokine responses, restorin |
|
DCC3509 |
Mtdl-4e
Novel resveratrol-based multitarget-directed ligand, cellularly activating the NRF2-ARE pathway (CD = 9.83 μM), selectively inhibiting both hMAO-B and QR2 (IC 50 s = 8.05 and 0.57 μM), and promoting hippocampal neurogenesis |
|
DCC3510 |
Mthp Hydrobromide
Selective antagonist of melanocortin-4 receptor (MC4R) |
325959-81-7 |
DCC3511 |
Mtmox32e
Novel Mithramycin A (MTM) 2'-oxime (MTMox) conjugate, displaying an 11-fold increase in plasma exposure and improved efficacy in an Ewing sarcoma xenograft |
|
DCC3512 |
Mtor Inhibitor-7
Novel, potent, and selective brain-penetrant ATP-competitive mTOR inhibitor |
|
DCC3513 |
Mtor/hdac1-in-12l
Novel potent dual inhibitor of mTOR and HDAC1 |
|
DCC3514 |
Mtorc1-in-1
Novel selective inhibitor of mTORC1, yielding potent inhibition of glucose uptake |
|
DCC3515 |
Mtorc1-in-i
Novel selective mTORC1 inhibitor, directly targeting class I glucose transporters |
|
DCC3516 |
Mtor-in-17
Novel mTOR inhibitor, exhibiting potent anticancer activities against four tumor cell lines, including MCF-7, HeLa, MGC-803, and C6, inducing cell death via apoptosis by targeting both mTORC1 and mTORC2 within cells and arrests the cell cycle of HeLa at t |
|
DCC3517 |
Mtpdds
Novel mitochondria-targeted photoactivatable real-time probe, being phototriggered by either UV (one-photon) or NIR (two-photon) light to form a fluorescent coumarin product and facilitate the release of drug payload |
|
DCC3518 |
Mtsea Hydrobromide
Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
16599-33-0 |
DCC3519 |
Mtsea Hydrochloride
Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
37597-96-9 |
DCC3520 |
Multitarget Ligand B6
Novel potent multitarget ligand |
220459-72-3 |
DCC3521 |
Mura-in-1 (zinc6129841)
Novel potent MurA inhibitor |
577789-80-1 |
DCC3522 |
Murizatoclax
Novel potent and selective MCL-1 inhibitor |
2245848-05-7 |
DCC3523 |
Mutant Idh1 Inhibitor
Novel potent mutant IDH1 R132H inhibitor |
1429180-08-4 |
DCC3524 |
Mv061194
Novel potent and selective cathepsin K (Cat K) inhibitor |
1021423-50-6 |
DCC3525 |
Mw01-2-151srm
CNS-penetrant, selective restorer of injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. Selective suppressor of beta amyloid (Aβ)-induced glia proinflammatory cytokine production |
886208-65-7 |
DCC3526 |
mw1219
Novel GPR119 agonist with Anti-Diabetic Efficacy in db/db Mice |
54087-06-8 |
DCC3527 |
Mwp00839
Novel mitophagy activator |
|
DCC3528 |
mycothiol
Major thiol in most actinomycetes involved in mycothiol biosynthesis and mycothiol-dependent enzymes such as mycothiol-dependent formaldehyde dehydrogenase and mycothione reductase |
192126-76-4 |
DCC3529 |
Mycro1
Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
313987-85-8 |
DCC3530 |
Mycro2
Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
314049-21-3 |
DCC3531 |
My-d-4
Novel inhibitor of zinc finger DHHC domain-containing (zDHHC) enzymes |
|
DCC3532 |
Myotoxin Ii (105-117)
Myotoxin II fragment |
223596-96-1 |
DCC3533 |
myovin-1
Novel potent, reversible and uncompetitive inhibitor of actin-stimulated ATPase activity of myosin V |
1259177-59-7 |
DCC3534 |
Myra-a
Novel inducer of apoptosis in a Myc-dependent manner, inhibiting Myc-driven transformation and disrupting MYC-Max interaction |
3900-43-4 |
DCC3535 |
Myrtucommulone
Inhibitor of the chaperonin activity of HSP60, correlating to LONP and LRP130 aggregation |
54247-21-1 |
DCC3536 |
Myxopyronin A
Bacterial RNA polymerase (RNAP) inhibitor |
88192-98-7 |
DCC3537 |
Mzp-54
Novel potent and selective PROTAC degrader of BRD3/4 |
2010159-47-2 |
DCC3538 |
N,n-dimethylsphingosine
Competitive inhibitor of both SPHK1 and SPHK2 |
119567-63-4 |
DCC3539 |
n00236460
Glucokinase activator (GKA) |
1466419-40-8 |
DCC3540 |
N6-allyladenosine
Novel RNA labeling probe through both metabolic and enzyme-assisted manners |
15763-12-9 |
DCC3541 |
N6-methyl-d3-adenosine
Deuterium labeled m6A used in important m6A physiological pathways related studies |
139896-43-8 |
DCC3542 |
Na-aaf
Alkylating agent, forming DNA adducts at the C-8 position in guanine, resulting in single strand breaks, demonstrating carcinogenic action |
6098-44-8 |
DCC3543 |
Nabiximols
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity |
56575-23-6 |
DCC3544 |
N-acetylloline
Derivative of loline |
4914-36-7 |
DCC3545 |
N-adamantanylglycinamide Hbr
Novel antiviral agent against the replication of influenza virus A/H3N2 subtype in Madin-Darby canine kidney (MDCK) cells |
54993-13-4 |
DCC3546 |
Nadide
Coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage |
53-84-9 |
DCC3547 |
Nadph Tetrasodium Salt
Electron donor and cofactor for many redox enzymes including nitric oxide synthetase |
2646-71-1 |
DCC3548 |
Nafoxidine
Partial estrogen antagonist, inhibiting angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), inducing oxidative stress, protein kinase C and calcium signaling |
1845-11-0 |
DCC3549 |
Nag-26
Novel potent full agonist for orexin receptor |
|
DCC3550 |
Nai003
Novel highly selective antibacterial agent against Propionibacterium acnes |
1888304-21-9 |
DCC3551 |
Nalbuphine Hydrochloride
Mixed agonist/antagonist opioid modulator, binding with high affinity to the MOR and KOR, and having relatively low affinity for the DOR |
23277-43-2 |
DCC3552 |
Naph-o2
Novel fluorescent probe for detection of endogenously produced Naph-O2˙– in living cells and tissues |
|
DCC3553 |
Naphthyridine-azaquinolone
Novel repeat-structure-specific DNA ligand, specifically binding slipped-CAG DNA intermediates of expansion mutations |
|
DCC3554 |
Naphyrone Hydrochloride
Triple reuptake inhibitor |
850352-11-3 |
DCC3555 |
Napi2b Inhibitor 15
Novel Gut-Restricted Inhibitor of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia |
|
DCC3556 |
Napitane Mesylate
Antagonist of alpha-2 adrenergic receptors and inhibitor of the neuronal uptake of norepinephrine |
149189-73-1 |
DCC3557 |
Napsagatran
Inhibitor of extrinsic and intrinsic thrombin generation, inhibiting clot-bound and free (fluid-phase thrombin) |
159668-20-9 |
DCC3558 |
N-arachidonoyl Taurine
Activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 |
119959-65-8 |
DCC3559 |
Nargenicin
Natural DnaE1 blocker, inducing a DNA damage response in Mycobacterium tuberculosis (Mtb) and inhibiting growth by blocking the replicative DNA polymerase, DnaE1 |
70695-02-2 |
DCC3560 |
Tylophorine
Potent suppressor of inducible nitric oxide synthase (iNOS; NOS II) |
482-20-2 |
DCC3561 |
Nav1.1-in-b
Novel selective NaV1.1 inhibitor, reducing visceral hypersensitivity |
924862-21-5 |